FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154045653> ?p ?o ?g. }

• W2154045653 endingPage "12" @default.
• W2154045653 startingPage "3" @default.
• W2154045653 abstract "Objective: The objective of this study was to assess the effect of treatment with interferon (IFN) β-1a, 44 µg subcutaneously (sc) three times weekly (tiw), on clinical and magnetic resonance imaging (MRI) outcomes in patients with relapsing multiple sclerosis (MS) following mitoxantrone therapy. Methods: This was an open-label, randomized, multicentre, rater-blinded, 96-week observational study conducted in Germany. Clinically stable patients with relapsing forms of MS, who had discontinued mitoxantrone treatment 1–6 months before study entry, were randomized to IFN β-1a sc 44 µg tiw, or no treatment. The primary endpoint was time to first relapse. Secondary endpoints included the number of relapse-free patients, disease activity assessed by MRI and time to 3-month confirmed Expanded Disability Status Scale (EDSS) progression, all at week 96. Results: A total of 30 patients were randomized (intent-to-treat population: 14 IFN β-1a, 15 untreated; one patient from the safety population discontinued the study after 25 days owing to an adverse event and without providing any postbaseline efficacy data, and was thus excluded from the intent-to-treat population). Overall, 71.4% (10/14) of patients in the IFN β-1a group remained relapse free over 96 weeks, versus 46.7% (7/15) in the untreated group ( p = 0.26). IFN β-1a delayed the time to first relapse versus no treatment ( p = 0.14); time to first relapse (25th percentile) was 95.4 (IFN β-1a) versus 46.0 weeks (no treatment). Confirmed EDSS progression was observed in five patients in each treatment group. Mean change in EDSS score was 0.3 in both groups ( p = 0.79). Changes in the number or volume of T1 and T2 lesions at week 96 were not significantly different between treatment groups ( p > 0.05). There were no new or unexpected adverse events related to IFN β-1a treatment. Conclusions: Several endpoints appeared to show a benefit of IFN β-1a treatment, but no significant differences could be detected owing to the small sample. Therefore, these data only permit, at best, tentative conclusions about the disease course in patients with MS after de-escalation from mitoxantrone and continuation with or without IFN β-1a. Larger confirmatory studies are required." @default.
• W2154045653 created "2016-06-24" @default.
• W2154045653 creator A5003973934 @default.
• W2154045653 creator A5050846374 @default.
• W2154045653 creator A5055558719 @default.
• W2154045653 creator A5062220148 @default.
• W2154045653 creator A5063615479 @default.
• W2154045653 creator A5064948864 @default.
• W2154045653 creator A5069481185 @default.
• W2154045653 date "2011-11-08" @default.
• W2154045653 modified "2023-09-27" @default.
• W2154045653 title "Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis" @default.
• W2154045653 cites W145182321 @default.
• W2154045653 cites W1964683464 @default.
• W2154045653 cites W1969554567 @default.
• W2154045653 cites W1969968445 @default.
• W2154045653 cites W1983925353 @default.
• W2154045653 cites W1992954578 @default.
• W2154045653 cites W2012054969 @default.
• W2154045653 cites W2026413027 @default.
• W2154045653 cites W2099462160 @default.
• W2154045653 cites W2105053272 @default.
• W2154045653 cites W2105477343 @default.
• W2154045653 cites W2110477182 @default.
• W2154045653 cites W2117852626 @default.
• W2154045653 cites W2119172537 @default.
• W2154045653 cites W2144633544 @default.
• W2154045653 cites W2148814846 @default.
• W2154045653 cites W2169098250 @default.
• W2154045653 cites W2509277703 @default.
• W2154045653 cites W26528964 @default.
• W2154045653 doi "https://doi.org/10.1177/1756285611428503" @default.
• W2154045653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3251902" @default.
• W2154045653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22276072" @default.
• W2154045653 hasPublicationYear "2011" @default.
• W2154045653 type Work @default.
• W2154045653 sameAs 2154045653 @default.
• W2154045653 citedByCount "12" @default.
• W2154045653 countsByYear W21540456532012 @default.
• W2154045653 countsByYear W21540456532013 @default.
• W2154045653 countsByYear W21540456532014 @default.
• W2154045653 countsByYear W21540456532015 @default.
• W2154045653 countsByYear W21540456532017 @default.
• W2154045653 countsByYear W21540456532018 @default.
• W2154045653 countsByYear W21540456532020 @default.
• W2154045653 crossrefType "journal-article" @default.
• W2154045653 hasAuthorship W2154045653A5003973934 @default.
• W2154045653 hasAuthorship W2154045653A5050846374 @default.
• W2154045653 hasAuthorship W2154045653A5055558719 @default.
• W2154045653 hasAuthorship W2154045653A5062220148 @default.
• W2154045653 hasAuthorship W2154045653A5063615479 @default.
• W2154045653 hasAuthorship W2154045653A5064948864 @default.
• W2154045653 hasAuthorship W2154045653A5069481185 @default.
• W2154045653 hasBestOaLocation W21540456532 @default.
• W2154045653 hasConcept C126322002 @default.
• W2154045653 hasConcept C141071460 @default.
• W2154045653 hasConcept C168563851 @default.
• W2154045653 hasConcept C197934379 @default.
• W2154045653 hasConcept C203014093 @default.
• W2154045653 hasConcept C203092338 @default.
• W2154045653 hasConcept C2776694085 @default.
• W2154045653 hasConcept C2779134260 @default.
• W2154045653 hasConcept C2780640218 @default.
• W2154045653 hasConcept C2780892749 @default.
• W2154045653 hasConcept C2780923524 @default.
• W2154045653 hasConcept C2781004633 @default.
• W2154045653 hasConcept C2908647359 @default.
• W2154045653 hasConcept C2908698914 @default.
• W2154045653 hasConcept C2994247566 @default.
• W2154045653 hasConcept C71924100 @default.
• W2154045653 hasConcept C90924648 @default.
• W2154045653 hasConcept C99454951 @default.
• W2154045653 hasConceptScore W2154045653C126322002 @default.
• W2154045653 hasConceptScore W2154045653C141071460 @default.
• W2154045653 hasConceptScore W2154045653C168563851 @default.
• W2154045653 hasConceptScore W2154045653C197934379 @default.
• W2154045653 hasConceptScore W2154045653C203014093 @default.
• W2154045653 hasConceptScore W2154045653C203092338 @default.
• W2154045653 hasConceptScore W2154045653C2776694085 @default.
• W2154045653 hasConceptScore W2154045653C2779134260 @default.
• W2154045653 hasConceptScore W2154045653C2780640218 @default.
• W2154045653 hasConceptScore W2154045653C2780892749 @default.
• W2154045653 hasConceptScore W2154045653C2780923524 @default.
• W2154045653 hasConceptScore W2154045653C2781004633 @default.
• W2154045653 hasConceptScore W2154045653C2908647359 @default.
• W2154045653 hasConceptScore W2154045653C2908698914 @default.
• W2154045653 hasConceptScore W2154045653C2994247566 @default.
• W2154045653 hasConceptScore W2154045653C71924100 @default.
• W2154045653 hasConceptScore W2154045653C90924648 @default.
• W2154045653 hasConceptScore W2154045653C99454951 @default.
• W2154045653 hasIssue "1" @default.
• W2154045653 hasLocation W21540456531 @default.
• W2154045653 hasLocation W21540456532 @default.
• W2154045653 hasLocation W21540456533 @default.
• W2154045653 hasLocation W21540456534 @default.
• W2154045653 hasOpenAccess W2154045653 @default.
• W2154045653 hasPrimaryLocation W21540456531 @default.
• W2154045653 hasRelatedWork W170712426 @default.

• next